<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34817583</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine.</ArticleTitle><Pagination><StartPage>e2135044</StartPage><MedlinePgn>e2135044</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2135044</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2021.35044</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Live attenuated vaccines may provide short-term protection against infectious diseases through stimulation of the innate immune system.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate whether passive exposure to live attenuated poliovirus is associated with diminished symptomatic infection with SARS-CoV-2.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In a longitudinal cohort study involving 87&#x202f;923 people conducted between March 20 and December 20, 2020, the incidence of COVID-19 was compared between 2 groups of aged-matched women with and without exposure to live attenuated poliovirus in the oral polio vaccine (OPV). Participants were people receiving health care services from the Petroleum Industry Health Organization and residing in 2 cities in Iran (ie, Ahwaz and Shiraz). Participants were women aged 18 to 48 years whose children were aged 18 months or younger and a group of age-matched women from the same residence who had had no potential exposure to OPV.</AbstractText><AbstractText Label="EXPOSURES">Indirect exposure to live attenuated poliovirus in OPV.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Symptomatic COVID-19, diagnosed by reverse transcription-polymerase chain reaction.</AbstractText><AbstractText Label="RESULTS">After applying the inclusion and exclusion criteria, 419 mothers (mean [SD] age, 35.5 [4.9] years) indirectly exposed to the OPV and 3771 age-matched women (mean [SD] age, 35.7 [5.3] years) who had no exposure to OPV were available for analysis. COVID-19 was diagnosed in 1319 of the 87&#x202f;923 individuals in the study population (151 per 10&#x202f;000 population) during the study period. None of the mothers whose children received OPV developed COVID-19 after a median follow-up of 141 days (IQR, 92-188 days; range, 1-270 days); 28 women (0.74%; 95% CI, 0.47%-1.02%) in the unexposed group were diagnosed with COVID-19 during the 9 months of the study. Point-by-point comparison of the survival curves of the exposed and unexposed groups found that indirect exposure to OPV was significantly associated with decreased COVID-19 acquisition; probability of remaining without infection was 1.000 (95% CI, 1.000-1.000) in the exposed group vs 0.993 (95% CI, 0.990-0.995) in the unexposed group after 9 months (P&#x2009;&lt;&#x2009;.001).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this cohort study, indirect exposure to live attenuated poliovirus was associated with decreased symptomatic infection with COVID-19. Further study of the potential protective effect of OPV should be conducted, especially in nations where OPV is already in use for polio prevention and specific COVID-19 vaccines are delayed, less affordable, or fail to meet demand.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Habibzadeh</LastName><ForeName>Farrokh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Global Virus Network, Middle East Region, Shiraz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>R&amp;D Headquarters, Petroleum Industry Health Organization, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sajadi</LastName><ForeName>Mohammad M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Virus Network, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chumakov</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Office of Vaccines Research and Review, Food and Drug Administration, Global Virus Network Center of Excellence, Silver Spring, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadollahie</LastName><ForeName>Mahboobeh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>R&amp;D Headquarters, Petroleum Industry Health Organization, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kottilil</LastName><ForeName>Shyamasundaran</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Virus Network, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simi</LastName><ForeName>Ashraf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>R&amp;D Headquarters, Petroleum Industry Health Organization, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stafford</LastName><ForeName>Kristen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Virus Network, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saeidimehr</LastName><ForeName>Saeid</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Petroleum Industry Health Organization, Ahwaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rafiei</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Petroleum Industry Health Organization Headquarters, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallo</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Virus Network, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Netw Open. 2021 Dec 1;4(12):e2143970. doi: 10.1001/jamanetworkopen.2021.43970</RefSource><PMID Version="1">34889951</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Kottilil reported receiving grants from the National Institutes of Health and Gilead and serving on the advisory boards of Merck and Regeneron outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>24</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34817583</ArticleId><ArticleId IdType="pmc">PMC8613592</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.35044</ArticleId><ArticleId IdType="pii">2786548</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johns Hopkins University . Coronavirus resource center. Accessed September 19, 2021. https://coronavirus.jhu.edu/map.html</Citation></Reference><Reference><Citation>Krause PR, Fleming TR, Longini IM, et al. ; WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation . Placebo-controlled trials of COVID-19 vaccines&#x2014;why we still need them. N Engl J Med. 2021;384(2):e2 doi:10.1056/NEJMp2033538</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2033538</ArticleId><ArticleId IdType="pubmed">33264543</ArticleId></ArticleIdList></Reference><Reference><Citation>Joffe S. Evaluating SARS-CoV-2 vaccines after emergency use authorization or licensing of initial candidate vaccines. JAMA. 2021;325(3):221-222. doi:10.1001/jama.2020.25127</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.25127</ArticleId><ArticleId IdType="pubmed">33315069</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092-2101. doi:10.1056/NEJMoa2104840</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104840</ArticleId><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. COVID-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ. 2021;372(n699):n699. doi:10.1136/bmj.n699</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n699</ArticleId><ArticleId IdType="pubmed">33707182</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibmer CK, Ayres F, Hermanus T, et al. . SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Med. 2021;27:622&#x2013;625. doi:10.1038/s41591-021-01285-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01285-x</ArticleId><ArticleId IdType="pubmed">33654292</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreano E, Piccini G, Licastro D, et al. . SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. Preprint published December 28, 2020. doi:10.1101/2020.12.28.424451</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.28.424451</ArticleId><ArticleId IdType="pmc">PMC8433494</ArticleId><ArticleId IdType="pubmed">34417349</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell. 2021;184(7):1671-1692. doi:10.1016/j.cell.2021.02.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.029</ArticleId><ArticleId IdType="pmc">PMC7885626</ArticleId><ArticleId IdType="pubmed">33743212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K, Benn CS, Aaby P, Kottilil S, Gallo R. Can existing live vaccines prevent COVID-19? Science. 2020;368(6496):1187-1188. doi:10.1126/science.abc4262</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc4262</ArticleId><ArticleId IdType="pubmed">32527819</ArticleId></ArticleIdList></Reference><Reference><Citation>Upfill-Brown A, Taniuchi M, Platts-Mills JA, et al. . Nonspecific effects of oral polio vaccine on diarrheal burden and etiology among Bangladeshi infants. Clin Infect Dis. 2017;65(3):414-419. doi:10.1093/cid/cix354</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix354</ArticleId><ArticleId IdType="pmc">PMC5848225</ArticleId><ArticleId IdType="pubmed">28444240</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov MP, Voroshilova MK, Antsupova AS, et al. . Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases. Article in Russian. Zh Mikrobiol Epidemiol Immunobiol. 1992;(11-12):37-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">1338742</ArticleId></ArticleIdList></Reference><Reference><Citation>Voroshilova MK. Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol. 1989;36:191-202.</Citation><ArticleIdList><ArticleId IdType="pubmed">2555836</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ. 1995;311(7003):481-485. doi:10.1136/bmj.311.7003.481</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.311.7003.481</ArticleId><ArticleId IdType="pmc">PMC2550544</ArticleId><ArticleId IdType="pubmed">7647643</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Soares-Weiser K, L&#xf3;pez-L&#xf3;pez JA, et al. . Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016;355:i5170. doi:10.1136/bmj.i5170</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i5170</ArticleId><ArticleId IdType="pmc">PMC5063034</ArticleId><ArticleId IdType="pubmed">27737834</ArticleId></ArticleIdList></Reference><Reference><Citation>Benyesh-Melnick M, Melnick JL, Rawls WE, et al. . Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol. 1967;86(1):112-136. doi:10.1093/oxfordjournals.aje.a120717</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a120717</ArticleId><ArticleId IdType="pubmed">4378110</ArticleId></ArticleIdList></Reference><Reference><Citation>Moradi-Lakeh M, Esteghamati A. National immunization program in Iran: whys and why nots. Hum Vaccin Immunother. 2013;9(1):112-114. doi:10.4161/hv.22521</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.22521</ArticleId><ArticleId IdType="pmc">PMC3667923</ArticleId><ArticleId IdType="pubmed">23442584</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajadi MM, Habibzadeh P, Vintzileos A, Shokouhi S, Miralles-Wilhelm F, Amoroso A. Temperature, humidity, and latitude analysis to estimate potential spread and seasonality of coronavirus disease 2019 (COVID-19). JAMA Netw Open. 2020;3(6):e2011834. doi:10.1001/jamanetworkopen.2020.11834</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.11834</ArticleId><ArticleId IdType="pmc">PMC7290414</ArticleId><ArticleId IdType="pubmed">32525550</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman VM, Landt O, Kaiser M, et al. . Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3). doi:10.2807/1560-7917.ES.2020.25.3.2000045</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.3.2000045</ArticleId><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Software. 2011;42(8):1-28. doi:10.18637/jss.v042.i08</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v042.i08</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau TM, Lumley T. survival: Survival analysis. Accessed May 10, 2021. https://CRAN.R-project.org/package=survival</Citation></Reference><Reference><Citation>Schober P, Vetter TR. Survival analysis and interpretation of time-to-event data: the tortoise and the hare. Anesth Analg. 2018;127(3):792-798. doi:10.1213/ANE.0000000000003653</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000003653</ArticleId><ArticleId IdType="pmc">PMC6110618</ArticleId><ArticleId IdType="pubmed">30015653</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. Springer; 1988.</Citation></Reference><Reference><Citation>Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39(2):499-503. doi:10.2307/2531021</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2531021</ArticleId><ArticleId IdType="pubmed">6354290</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozenfeld Y, Beam J, Maier H, et al. . A model of disparities: risk factors associated with COVID-19 infection. Int J Equity Health. 2020;19(1):126. doi:10.1186/s12939-020-01242-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12939-020-01242-z</ArticleId><ArticleId IdType="pmc">PMC7387879</ArticleId><ArticleId IdType="pubmed">32727486</ArticleId></ArticleIdList></Reference><Reference><Citation>Gesesew HA, Koye DN, Fetene DM, et al. . Risk factors for COVID-19 infection, disease severity and related deaths in Africa: a systematic review. BMJ Open. 2021;11(2):e044618. doi:10.1136/bmjopen-2020-044618</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-044618</ArticleId><ArticleId IdType="pmc">PMC7896374</ArticleId><ArticleId IdType="pubmed">33602714</ArticleId></ArticleIdList></Reference><Reference><Citation>Habibzadeh F, Yadollahie M, Simi A, et al. . Accessing free quality health care services and premature death. Int J Health Plann Manage. 2019;34(2):594-603. doi:10.1002/hpm.2720</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hpm.2720</ArticleId><ArticleId IdType="pubmed">30536983</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaug M. The correlation between education and earnings: what does it signify? Higher Educ. 1972;1(1):53-76. doi:10.1007/BF01956881</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01956881</ArticleId></ArticleIdList></Reference><Reference><Citation>Habibzadeh F. Economic sanction: a weapon of mass destruction. Lancet. 2018;392(10150):816-817. doi:10.1016/S0140-6736(18)31944-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31944-5</ArticleId><ArticleId IdType="pubmed">30139528</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K, Avidan MS, Benn CS, et al. . Old vaccines for new infections: exploiting innate immunity to control COVID-19 and prevent future pandemics. Proc Natl Acad Sci U S A. 2021;118(21):e2101718118. doi:10.1073/pnas.2101718118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2101718118</ArticleId><ArticleId IdType="pmc">PMC8166166</ArticleId><ArticleId IdType="pubmed">34006644</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea MG, Dom&#xed;nguez-Andr&#xe9;s J, Barreiro LB, et al. . Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375-388. doi:10.1038/s41577-020-0285-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0285-6</ArticleId><ArticleId IdType="pmc">PMC7186935</ArticleId><ArticleId IdType="pubmed">32132681</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng SC, Quintin J, Cramer RA, et al. . mTOR- and HIF-1&#x3b1;-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345(6204):1250684. doi:10.1126/science.1250684</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1250684</ArticleId><ArticleId IdType="pmc">PMC4226238</ArticleId><ArticleId IdType="pubmed">25258083</ArticleId></ArticleIdList></Reference><Reference><Citation>Arts RJ, Novakovic B, Ter Horst R, et al. . Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab. 2016;24(6):807-819. doi:10.1016/j.cmet.2016.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2016.10.008</ArticleId><ArticleId IdType="pmc">PMC5742541</ArticleId><ArticleId IdType="pubmed">27866838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekkering S, Arts RJW, Novakovic B, et al. . Metabolic induction of trained immunity through the mevalonate pathway. Cell. 2018;172(1-2):135-146.e9. doi:10.1016/j.cell.2017.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.11.025</ArticleId><ArticleId IdType="pubmed">29328908</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed S, Quintin J, Kerstens HH, et al. . Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014;345(6204):1251086. doi:10.1126/science.1251086</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1251086</ArticleId><ArticleId IdType="pmc">PMC4242194</ArticleId><ArticleId IdType="pubmed">25258085</ArticleId></ArticleIdList></Reference><Reference><Citation>Habibzadeh F, Habibzadeh P, Yadollahie M. On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem Med (Zagreb). 2016;26(3):297-307. doi:10.11613/BM.2016.034</Citation><ArticleIdList><ArticleId IdType="doi">10.11613/BM.2016.034</ArticleId><ArticleId IdType="pmc">PMC5082211</ArticleId><ArticleId IdType="pubmed">27812299</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>